Developer docs
API playgroundTry for free, no card

Search company profiles

Endymed

Full company profile

uuid0006kbl

Namestring
Endymed
Websiteurl
endymed.com
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCaesarea, Israel
HQ citystring
Caesarea
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
aesthetic medical devices, radiofrequency microneedling, energy-based aesthetics, skin rejuvenation devices, dermatology equipment
Industry4 codes
1Laser & Energy-Based Dermatology
CodeHLAKACAFPrimaryNo
2Anti-Aging & Firming Treatments
CodeHSALADACPrimaryNo
3Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning)
CodeCRABAKAIPrimaryNo
4Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices)
CodeCRABAAAJPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Aesthetic Medical Devices
Social media profiles3 records
Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Endymed Ltd designs, manufactures, and sells radiofrequency (RF) energy-based aesthetic medical devices, including RF microneedling systems, for non-invasive skin treatments such as skin rejuvenation, anti-aging, skin tightening, and facial treatments. The company's devices are used by dermatologists, plastic surgeons, and aesthetic practitioners and have received FDA approval for facial treatment applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Endymed offers radiofrequency-based aesthetic devices for non-invasive skin treatments. Based on available sources, the company holds FDA approval for facial treatment applications within the RF microneedling and skin rejuvenation device category. The specific product portfolio details, naming, and architecture could not be extracted as the company website (endymed.com) was not accessible during data collection, returning only a verification/loading page.

Product and service1 record
1Endymed RF Aesthetic Device
CategoryEnergy-based aesthetic devices
Description

Radiofrequency-based aesthetic device with FDA approval for facial treatment applications, used by dermatologists and aesthetic practitioners for non-invasive skin rejuvenation, anti-aging, and skin tightening procedures.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Endymed

Aesthetic Medical Devicesendymed.com

Endymed firmographics

Firmographics
Name
Endymed
Website
https://endymed.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Endymed is headquartered

Location

Headquarters

HQ city
Caesarea
HQ country
Israel
HQ region
Middle East

Markets served

Endymed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Endymed product offering

Product offering

Core offering

Endymed Ltd designs, manufactures, and sells radiofrequency (RF) energy-based aesthetic medical devices, including RF microneedling systems, for non-invasive skin treatments such as skin rejuvenation, anti-aging, skin tightening, and facial treatments. The company's devices are used by dermatologists, plastic surgeons, and aesthetic practitioners and have received FDA approval for facial treatment applications.

Product overview

Endymed offers radiofrequency-based aesthetic devices for non-invasive skin treatments. Based on available sources, the company holds FDA approval for facial treatment applications within the RF microneedling and skin rejuvenation device category. The specific product portfolio details, naming, and architecture could not be extracted as the company website (endymed.com) was not accessible during data collection, returning only a verification/loading page.

Differentiator

Problem solved

Functional benefit

Products and services

  • Endymed RF Aesthetic Device Radiofrequency-based aesthetic device with FDA approval for facial treatment applications, used by dermatologists and aesthetic practitioners for non-invasive skin rejuvenation, anti-aging, and skin tightening procedures.

Companies that use Endymed

Customer profile

Ideal customer profiles1 record

Endymed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Endymed partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

Endymed competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat3 records

Customer concentration

Endymed social profiles

Digital presence

Endymed compliance and trust

Trust signal

Compliance1 record

Endymed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Endymed leadership team

Management profile

Number of profiles

Profiles1 record

Endymed funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Endymed M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endymed

What does Endymed do?

Endymed Ltd designs, manufactures, and sells radiofrequency (RF) energy-based aesthetic medical devices, including RF microneedling systems, for non-invasive skin treatments such as skin rejuvenation, anti-aging, skin tightening, and facial treatments. The company's devices are used by dermatologists, plastic surgeons, and aesthetic practitioners and have received FDA approval for facial treatment applications.

Is Endymed a public or private company?

Endymed is a private company. It is classified as public and is currently operating.

When was Endymed founded?

Endymed was founded in 2004. It employs 11 to 50 people.

Where is Endymed based?

Endymed is headquartered in Caesarea, Israel, in the Middle East region.

Does Endymed have an API?

No public API is recorded for Endymed.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInMarket Trends and Growth for RF Microneedling Skin Care Technology Industry with a 10.6% CAGR Forecast from 2025 to 2032A market research report forecasts the RF Microneedling Skin Care Technology industry will grow at a 10.6% CAGR from 2025 to 2032, driven by rising demand for minimally invasive aesthetic procedures and technological advancements. The analysis identifies key competitive players including Lumenis, Cutera, Endymed, and Candela, who are investing in R&D to capture market share in North America, Europe, and Asia-Pacific.LinkedInMicroneedling Devices in Aesthetic Medicine Market Emerging Technologies Outlook 2026–2033Verified Market Reports has published a market analysis forecasting the global microneedling devices in aesthetic medicine market to grow from $3.2 billion in 2024 to $7.5 billion by 2033, driven by demand for minimally invasive skin rejuvenation and technological innovations. The report highlights key industry players such as Jeisys, EndyMed, and Candela Medical, noting that growth is fueled by consumer awareness of non-surgical options and regulatory advancements in device safety.LinkedInRF Microneedling Skin Care Technology Market Signals 2025: Strategic Tech Adoption RoadmapVerified Market Reports has published a market analysis projecting the global RF Microneedling Skin Care Technology Market to grow from USD 350 million in 2024 to USD 1.2 billion by 2033, driven by rising consumer demand for minimally invasive aesthetic procedures and technological advancements. The report identifies key industry players such as Lumenis, Cutera, and Endymed as central to this expansion, which is further supported by increasing disposable incomes and strategic collaborations between manufacturers and healthcare providers.PR NewswireENDYMED Announces Full Merger with Its Majority Shareholder and Distributor in China, Strengthening Global Market PositionENDYMED completed its full merger with majority shareholder Shanghai Haohai Biological Technology Co., Ltd. The consolidation strengthens ENDYMED's Chinese market presence and global reach, streamlining supply chains and accelerating innovation. CEO Yossi Bar-On and Chairman Dr. Hou cited enhanced strategic flexibility and customer benefits.NoCamelsIsraeli Device Is New, Drug-Free Solution For Men Coping With EDIsraeli startup Ohh-Med has developed the Vertica device, a drug-free treatment for erectile dysfunction using radio frequency technology to stimulate collagen production and improve blood flow. The device, which achieved an over 85 percent success rate in clinical use, is currently approved in Australia, the European Union, Israel, and the United Kingdom, with commercial sales being planned in those regions. The company, founded in Tiberias in 2017 by former Endymed founder Daniel Lischinsky, is also undergoing FDA trials in the United States, where the technology requires separate authorization despite Endymed's prior FDA approval for a similar facial treatment.Market ScoopMicroneedling Market Value to Hit USD 35.3 Billion in 2033The global microneedling market is projected to grow from USD 10.3 billion in 2023 to USD 35.3 billion by 2033, driven by technological advancements like RF microneedling and rising demand for minimally invasive aesthetic treatments. Key industry players including Lumenis, Cutera, Cynosure, and Endymed are expanding their portfolios with new devices targeting skin rejuvenation and scar treatment. The Asia-Pacific region is expected to witness the fastest growth due to increasing disposable income and medical tourism.PR NewswireEndymed Received FDA Approval for Marketing and Sales of its Brand-New Laser based Hair Removal DeviceEndymed Ltd, a medical-aesthetic device company listed on the Tel Aviv Stock Exchange, has received FDA approval to market and sell its Pure Laser hair removal device in the United States. The device was developed by the company's subsidiary Endymed Medical Ltd using laser technology designed for hair removal on all skin types, following positive clinical tests demonstrating safety and efficacy. Endymed intends to commence US marketing through its subsidiary Endymed Medical Inc. and is pursuing registration and distribution agreements in other strategic countries.PR NewswireENDYMED appoints Dr. Ziv Karni, Founder of Alma Lasers as Expert Technology AdvisorEndymed Ltd, a medical-aesthetic device company traded on the Tel Aviv Stock Exchange, announced the appointment of Dr. Ziv Karni as Expert Technology Advisor. Dr. Karni, who founded Alma Lasers (sold in 2013 for $240 million), brings over 35 years of experience in medical laser research and development. The company described this appointment as a significant milestone to advance its 3DEEP radiofrequency technology portfolio and expand its presence in the global medical aesthetics market.PR NewswireA Chinese social media influencer sold approximately $ 1 million worth of Endymed's home use products within minutesEndymed, an Israeli medical-aesthetic device company, sold approximately $1 million worth of its home use device NEWA within minutes during a live broadcast by Chinese social media influencer Li Jiaqi on Alibaba's Tmall platform. The company's China/Hong Kong distributor, controlled by main shareholder OHMK Medical Technology, entered into the cooperation agreement that resulted in NEWA ranking first in sales in its category. The distributor has indicated it intends to continue the partnership with the influencer.PR NewswireEclipse Launches NEWA®, Home-Use RF Skin-Care SystemEclipse Aesthetics announced a partnership with EndyMed Medical Ltd. to launch the NEWA® home-use radiofrequency skin-care device in the United States, marking the first FDA-cleared RF device for aesthetic home-use. The device utilizes EndyMed's patented 3DEEP® RF technology and is clinically proven to reduce mild to moderate facial wrinkles. The award-winning system is now available through select dermatologists, plastic surgeons, and medical spas.